Eckert & Ziegler Strahlen & Medizintechnik AG provided earnings guidance for the full year of 2015. The sale of the shares in OctreoPharm Sciences GmbH to IPSEN took legal effect June 30, 2015 following the receipt of an initial payment. As a result, the Executive Board of the company has raised its profit forecast for 2015 to at least EUR 2.00 per share, or just over EUR 10 million.